Study wrapper · #1030
From FLOW to translational positioning in chronic kidney disease: mechanistic complementarity of SGLT2 inhibitors and GLP-1 receptor agonists.
Editor's note
A translational review positioning GLP-1 receptor agonists and SGLT2 inhibitors as mechanistically complementary in chronic kidney disease, anchored on the FLOW trial's kidney-outcome data for semaglutide. The piece is conceptual, synthesizing mechanism rather than reporting new data, and it flags as unresolved whether semaglutide's renal benefit extends to the whole GLP-1 class. Useful for readers interested in the biological rationale behind combination strategies.
Plain-language abstract
This review discusses how GLP-1 receptor agonists and SGLT2 inhibitors may complement each other in chronic kidney disease, citing the FLOW trial's kidney-outcome evidence for semaglutide. It frames the two drug classes as working through different but converging biological pathways.